Tecogen Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

Key Highlights for Investors

• Significant Net Loss Reported: Tecogen Inc. reported a net loss attributable to shareholders of \$(3.99) million for Q4 2025, a sharp increase from the net loss of \$(1.13) million in Q4 2024. On a per share basis, this equates to a basic and diluted net loss of \$(0.13) compared to \$(0.05) in the prior year period.
• Full Year Loss Deepens: For the year ended December 31, 2025, the net loss attributable to shareholders reached \$(8.18) million or \$(0.30) per share, compared to a net loss of \$(4.72) million or \$(0.19) per share for the previous year.
• Revenue Performance: Total revenues for Q4 2025 were \$1.17 million, compared to \$0.96 million in Q4 2024. For the full year 2025, total revenues amounted to \$6.10 million, up from \$3.87 million in 2024, reflecting growth in both products and services.
• Adjusted EBITDA Remained Negative: Adjusted EBITDA, a non-GAAP metric, was \$(2.43) million for Q4 2025 versus \$(0.69) million in Q4 2024. For the year, Adjusted EBITDA stood at \$(7.43) million, worsening from \$(2.87) million in 2024.
• Cash Position Bolstered by Equity Raise: The company completed a follow-on equity offering during the year, raising \$18.1 million net of transaction costs, which significantly increased cash and cash equivalents to \$17.40 million at year-end, compared to \$7.03 million at the end of 2024.
• Share Count Increases: Outstanding common shares rose to 29.85 million at year-end 2025 from 24.95 million at year-end 2024, primarily as a result of equity issuance and a related party note conversion to common stock (\$514,148).
• Operating Cash Flows Deep in the Red: Net cash used in operating activities was \$(4.67) million for 2025, highlighting ongoing negative operating performance.
• Stock-Based Compensation: Non-cash stock compensation expense increased to \$348,029 for the year, up from \$172,987 in 2024, reflecting grants to management and employees.
• Marketable Securities Activity: The company reported a realized gain on marketable securities of \$3,687 and an unrealized gain of \$10,993 for 2025.

Important Shareholder and Price-Sensitive Developments

• Massive Equity Capital Raise: The successful \$18.1 million equity offering strengthens the balance sheet and provides liquidity for operations and growth initiatives. However, the substantial increase in share count dilutes existing shareholders.
• Continued Operating Losses and Cash Burn: Despite higher revenues, the company’s losses have widened, and cash flow from operations remains negative, which may continue to pressure the share price unless profitability improves.
• Ongoing Use of Non-GAAP Metrics: Management continues to highlight Adjusted EBITDA as a measure of performance, but this figure remains deeply negative, underscoring ongoing operational challenges.
• Related Party Note Conversion: Conversion of a related party note to common stock (\$514,148) further increased outstanding shares, which may be viewed as dilutive by investors.
• Forward-Looking Risks Noted: The company disclosed material risks that could affect results and share value, including fluctuating product demand, technological developments, regulatory changes, and the ability to secure further financing on favorable terms.

Detailed Financial Summary

Forward-Looking Statements & Risks

Tecogen’s management cautions investors about forward-looking statements that include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “project,” “target,” “potential,” “will,” “should,” “could,” “likely,” or “may.” These statements are subject to risks and uncertainties that could cause actual results to differ materially. Key risks include fluctuating demand, competitive technologies, regulatory changes, research and development challenges, the availability of incentives, successful integration of acquisitions, and access to favorable financing.

The company undertakes no obligation to update or revise any forward-looking statements.

Contact Information

Tecogen Media & Investor Relations Contact:
Abinand Rangesh
P: 781-466-6487
E: [email protected]

Summary for Investors

Bottom Line: Tecogen’s Q4 and full year 2025 results highlight continued revenue growth but also deepening losses and ongoing negative operating cash flow. The substantial equity raise provides a critical cash buffer, but the increased share count is dilutive to existing shareholders. Persistent operating challenges and continued cash burn are key risks that could weigh on the share price. Investors should monitor the company’s pathway to profitability and any further capital needs closely.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All financial figures are as reported by Tecogen Inc. Investors should review the company’s official filings and consult their own advisors before making investment decisions. Forward-looking statements are subject to risks and uncertainties and actual results may differ materially.

View TECOGEN INC. Historical chart here